The price you pay for Soliris may depend on factors such as whether you have health insurance. Financial assistance may be available to help you with the cost of Soliris. your treatment plan your ...
The cost of Soliris can vary based on several factors, including your insurance coverage. Drug savings programs can also lower the price you’ll pay for Soliris. Soliris may need to be purchased ...
Alexion nabs potential $1B indication for Soliris, but it'll have to take on Roche's cheaper Rituxan
In an effort to protect its blockbuster Soliris, Alexion has employed a double strategy of nabbing additional approvals and positioning follow-up drug Ultomiris to switch over sales. Alexion added ...
FDA Approves Expanded Use of Eculizumab (Soliris) for Pediatric Myasthenia Gravis · GlobeNewswire Inc. New York, March 10, 2025 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) welcomes ...
Alexion's Soliris Granted Marketing Approval in Europe for Treatment of All Patients With PNH - First therapy approved in both Europe and the United States for rare and life-threatening blood disease ...
In its push to backstop sales of blockbuster Soliris, Alexion has touted its better-than-expected success at switching patients to follow-up drug Ultomiris. But if switching to the newer med is going ...
In the PREVENT study, the safety and efficacy of Soliris was compared to placebo in patients with AQP4 auto antibody-positive NMOSD (N=143). Treatment with Soliris (eculizumab; Alexion) was associated ...
The FDA approved a fourth indication for Alexion Pharmaceuticals’ brand-name eculizumab (Soliris) for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are ...
Apellis Pharmaceuticals’ pegcetacoplan has beaten Alexion’s blockbuster Soliris in a head-to-head phase 3 trial. The result suggests Apellis can challenge Alexion’s dominance in paroxysmal nocturnal ...
CHESHIRE, Conn.--(BUSINESS WIRE)-- Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that researchers are scheduled to present data from clinical studies of Soliris ® (eculizumab) in ...
Update: On September 29, 2021, Canada applied to the Supreme Court of Canada for leave to appeal (Docket No. 39858). According to the Board’s Guidelines, as a breakthrough drug, the highest price at ...
In September 2017, the Patented Medicine Prices Review Board (PMPRB) decided that Alexion’s SOLIRIS (eculizumab) was sold at an excessive price. In doing so, the Board departed from the Guidelines, in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results